Indeed, three large randomized controlled studies found that atorvastatin, pravastatin, and pitavastatin could decrease the level of alanine aminotransferase in patients with NAFLD [81–83]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.